– USA, CA – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the appointment of Dr. Ted Love (MD) to its Board of Directors.
“We are delighted to welcome Ted Love to the Gilead Board of Directors. Ted is a highly respected executive leader with decades of experience in the biopharma industry, most recently as CEO of a global healthcare company. Ted also has a strong scientific background, and his focus on access and inclusion aligns perfectly with Gilead’s values. Ted will be a valuable addition to the Gilead Board as we continue to expand our impact on patients and communities worldwide,” said Chairman and CEO, Daniel O’Day.
About Dr. Ted W. Love
Dr. Ted Love is chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and Structure Therapeutics. Previously, he was President and CEO of Global Blood Therapeutics, Inc. which he led from a pre-clinical startup to a global commercial company focusing on sickle cell disease. Prior, he was EVP of Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc.; President, CEO, and Chairman of Nuvelo, Inc.; and SVP of development at Theravance Biopharma, Inc. He began his biotech career at Genentech.
Dr. Love earned his MD from the Yale School of Medicine and completed a residency in Internal Medicine and a fellowship in cardiology at Massachusetts General Hospital.
Known for championing access to care, Dr. Love received the William E. Proudford Sickle Cell Fund 2023 Distinguished Service Award for addressing ongoing healthcare disparities facing the sickle cell disease community. In 2023, he also earned the Spirit of the Heart Health Equity Champion Award from the Association of Black Cardiologists.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, to create a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
SOURCE www.gilead.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
